ライフサイエンスコーパス: drug

1 hat, potentiate the response of cells to the drug.

2 tive methamphetamine use and craving for the drug.

3 The risk may vary by drug.

4 ution in vivo more efficiently than the free drug.

5 et cells convert to pharmacologically active drug.

6 requisite for using them as novel antibiotic drugs.

7 up but was judged not to be related to study drugs.

8 not compromising on the effectiveness of the drugs.

9 esigning new molecules toward AD therapeutic drugs.

10 represents a new class of sulfide-releasing drugs.

11 enable rapid screening of brain-penetrating drugs.

12 s for the sustained release of proteinaceous drugs.

13 erials, molecular motors, and photoactivated drugs.

14 esting a large structural diversity of these drugs.

15 s for the development of alternate antiviral drugs.

16 ine drugs and 32 days sooner for second-line drugs.

17 e the need for effective peripherally acting drugs.

18 and thus sensitise them to chemotherapeutic drugs.

19 have had previous exposure to antiretroviral drugs.

20 ns on a NINDS small molecule library of 1040 drugs.

21 benefit from drug therapy to not take these drugs.

22 nnecting diseases to potentially efficacious drugs.

23 of a MOF capable of separating chiral polar drugs.

24 he USA and concentrated in people who inject drugs.

25 pathways, and the effects of betaAR-directed drugs.

26 strongly with drug sensitivity for 14 of the drugs, 9 of which had no genomic biomarker.

27 nal changes as previously proposed for multi-drug ABC exporters.

28 rders (alcohol abuse, 96.5 [0.67]; P < .001; drug abuse, 97.6 [0.64]; P = .02), and specific phobia (

29 ociated comorbidities, such as dyslipidemia, drug abuse, and opportunistic infections; and lifestyle

30 lamine signaling has long been implicated in drug abuse.

31 nd eye were 0 and 1 point without any rescue drugs, accounted for 9 and 24% of total SLIT, respective

32 ts antiepileptic activity can be mimicked by drugs acting on serotonin signalling pathways e.g. trazo

33 ncer metabolism and its use in understanding drug actions.

34 This process is 'hijacked' by drug addiction, causing cue-induced cravings and relapse

35 suggesting that lowering the total amount of drug administered could lower toxicities while not compr

36 ure (LAAC) was approved by the U.S. Food and Drug Administration (FDA) as a stroke prevention alterna

37 nersen/Spinraza) was approved by US Food and Drug Administration (FDA) in late 2016 and several other

38 The Food and Drug Administration Adverse Event Reporting System (FAER

39 ends of Cancer Research, and the US Food and Drug Administration examined specific eligibility criter

40 rcial tests are cleared by the U.S. Food and Drug Administration for use with extragenital swab sampl

41 The United States Food and Drug Administration is concerned about the presence of t

42 did not identify deviations from US Food and Drug Administration or manufacturer recommendations for

43 olume deficits, but the proposed US Food and Drug Administration regulations may severely limit the a

44 sma HIV-1 RNA at week 48 (by the US Food and Drug Administration snapshot algorithm), with a prespeci

45 Mass drug administration was predicted to be more effective i

46 at simulates an intervention similar to mass drug administration, we argue that the observed repertoi

47 g-repurposing screening to identify Food and Drug Administration-approved chemotherapeutic compounds

48 for phase II to IV cancer trials of Food and Drug Administration-approved immunotherapy drugs and sel

49 omes larger under pathological conditions or drug administrations.

50 eting the vasculature, GSCs, and GECs, using drugs already approved by the FDA, can reduce both tumor

51 Moreover, binding of the antiviral drug, amantadine, at the N-terminal pore at low pH did n

52 icial effects of several of the antimalarial drugs (AMDs) on clinical features of autoimmune disorder

53 rt of the Yale-Penn study of the genetics of drug and alcohol dependence from February 14, 1999, to J

54 Individual patient data on SAEs, assigned drug and dosing regimen, and baseline prognostic factors

55 per protocol for all patients who commenced drug and included all patients who received at least one

56 ative in cells exposed to both perturbations-drug and mutation-compared with cells exposed to either

57 tumorigenic environment and are targets for drug and vaccine-based control measures.

58 r than with culture-based DST for first-line drugs and 32 days sooner for second-line drugs.

59 ed, including the identification of designer drugs and chemical derivatives not present in the librar

60 ility to evaluate and cross-compare multiple drugs and drug combinations simultaneously in living tum

61 ination of ligand selectivity both for small drugs and large proteins with nearly base-pair resolutio

62 d Drug Administration-approved immunotherapy drugs and selected those reporting results for both OS a

63 as a Phase II enzyme, activating cancer pro-drugs and stabilizing p53 and p73alpha oncosuppressors.

64 n of HIV-1 infection for migrants who inject drugs and to investigate whether transmissions occur mor

65 tudy polio pathogenesis, candidate antiviral drugs, and the efficacy of new vaccines.

66 TCL are sensitive to transcription-targeting drugs, and, in particular, to THZ1, a covalent inhibitor

67 baceous gland size, indicating that this pro-drug approach was critical to obtain the desired activit

68 ation by central delivery of the antimitotic drug arabinofuranosyl cytidine (AraC) blunted food intak

69 tructural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine sur

70 Drug assays with patient-derived cells such as circulati

71 was demonstrated with three different statin drugs (atorvastatin, rosuvastatin, and fluvastatin).

72 In this study, 16 drug biomarkers were selected, including the parent form

73 tes, optimizing manufacturing, and screening drugs/biomaterials.

74 applications, but also serves as a potential drug by which modulation of neural glycan biosynthesis a

75 olangitis and PSC in the hope that these new drugs can be used more effectively.

76 ity-dependent synaptic plasticity, addictive drugs can derail the experience-driven neural circuit re

77 suggest that myricetin might be a potential drug candidate for the treatment of T2DM as a GLP-1R ago

78 er 2 (SGLT2) inhibitors are highly promising drug candidates for the treatment of Type 2 diabetes mel

79 is on the efficacy of antimycobacterials and drug candidates, we subjected Nos2 (-/-) mice with TB to

80 dimers represent a major class of bispecific drug candidates.

81 Inorganic nanoparticles (NPs) are studied as drug carriers, radiosensitizers and imaging agents, and

82 aradigms at baseline and after psychotogenic drug challenge, in conjunction with remodeling of local

83 However, individual drug classes appear to occupy a narrow and unique space

84 ypertension in communities that had all four drug classes available were more likely to use at least

85 ed cell viability and resistance to specific drug classes in the BM stroma-derived conditions was a r

86 storage protein, demonstrate soaking of the drug colchicine into tubulin and native sulfur phasing o

87 We found that the overall drug collection covers a wide CCS range for the same mas

88 Furthermore, cells treated with the drug combination exhibited increased promoter and gene b

89 redictive of preclinical sensitivity to this drug combination.

90 valuate and cross-compare multiple drugs and drug combinations simultaneously in living tumors and ac

91 ed corresponding synergistic or antagonistic drug combinations.

92 howing statistical significance of the study drug compared to placebo ( P < 0.0161 and P < 0.0001, re

93 xosomes to active drug efflux increased with drug concentration and exceeded the p-glycoprotein efflu

94 phagy led to 50-fold increases in the plasma drug concentration of the viral integrase inhibitor dolu

95 Interestingly, we also predict that drug concentrations lower than the MTD are as efficaciou

96 ur countries were subjected to DST for eight drugs, confirmatory Wayne's assay, and whole-genome sequ

97 al story of GO, which was the first antibody-drug conjugate approved for human use by the FDA.

98 mab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimer

99 t strategies to produce homogeneous antibody-drug conjugates (ADCs) rely on mutations or inefficient

100 a per-vehicle basis as compared to antibody-drug conjugates (ADCs).

101 Here, we report that nanoparticle-drug conjugates (NDCs) of monomethyl auristatin E (MMAE)

102 BCs), may be a potential target for antibody-drug conjugates.

103 ility to precisely monitor the efficiency of drug conjugation with a catalytic assay.

104 nstruction of biomaterials that are used for drug delivery and multimodal imaging, among others.

105 linical implications, including concepts for drug delivery and new classifications and therapeutic op

106 rapid development of microneedle devices for drug delivery applications into skin.

107 will play a vital role in the future of the drug delivery field.

108 tor (CSF-1R) blockade and nanoparticle-based drug delivery in murine pulmonary carcinoma.

109 The present study reports a drug delivery system comprising nanostructured lipid car

110 ated to their applications in tumor-targeted drug delivery system research.

111 erapeutic micromotors application for active drug delivery to treat gastric bacterial infection in a

112 luding chemical sensing, biological imaging, drug delivery, and photothermal therapy.

113 hrough the application of nanoparticle-based drug delivery, opening several exciting avenues for sele

114 orward toward the development of implantable drug-delivery systems.

115 nebuliser that achieves significantly higher drug deposition in the lung compared with the existing f

116 ubsequent optimization using structure-based drug design, and parallel medicinal chemistry led to the

117 s will enable novel routes for PTP-selective drug design, important for managing diseases such as can

118 ations of GPCR conformational plasticity for drug design.

119 cating the high relevance of this cavity for drug design.

120 donor has been exploited in knowledge-based drug design.

121 important asset in future anti-inflammatory drug design.

122 ide a foundation from which to make informed drug development decisions.

123 with the same tumor type, this is an area of drug development that, rather than simply benefiting fro

124 y, we consider the implications for rational drug development, in particular regionally selective dop

125 us making this scaffold a good candidate for drug development.

126 ities, may be the basis for future liposomal drug development.

127 e the potential to improve the efficiency of drug development.

128 thereby substantially expediting the pace of drug development.

129 ovel anti-human immunodeficiency virus (HIV) drug development.IMPORTANCE The Vpr and its paralog Vpx

130 r types, may be a viable strategy for future drug development.SIGNIFICANCE STATEMENT Memantine and ke

131 nd VP24, represents an attractive target for drug development; however, the molecular determinants th

132 Emerging treatment concepts use drugs directed against KIT and other relevant targets in

133 ring fields are preserved under PCP, but the drug discoordinates the subsecond temporal organization

134 is burdened by many uncertainties that make drug discovery difficult.

135 enhance the sensitivity of C. elegans based drug discovery platforms.

136 es in optogenetics have opened new routes to drug discovery, particularly in neuroscience.

137 for applications in disease investigations, drug discovery, prosthetic design and neuropathic pain i

138 e development of cell-based assays for NMDAR drug discovery.

139 ted EGFR can help identify novel targets for drug discovery.

140 biological reagents for target validation in drug discovery.

141 cessory proteins provide a new dimension for drug discovery.

142 omise as a biomarker for diagnosis and novel drug discovery.

143 egenerative therapies, disease modeling, and drug discovery.

144 ich has led to renewed efforts in antibiotic drug discovery.

145 The unlabeled drug dose and plasma concentration leading to a 50% redu

146 ogen-independent cells and lowers cumulative drug dose.

147 nal magnetic resonance imaging (fMRI) in a 2-drug, double-blind placebo-controlled crossover design c

148 receptors exclusively activated by designer drugs (DREADDs) to selectively activate or inhibit ArcN

149 entified a range of small organic molecules, drugs, drug metabolites and drug-like molecules, includi

150 ents who received at least one dose of study drug during the maintenance period were included in the

151 ural differences to the demonstration of the drug effect.

152 in cerebral blood volume (CBV) as a proxy of drug effects on neuronal activity.

153 or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a m

154 to explore the possibility of extracting NAI drug efficacy using only the observed viral titer decay

155 ions, the contribution of exosomes to active drug efflux increased with drug concentration and exceed

156 ilizing the pericardial space as a sustained drug-eluting reservoir through the application of nanopa

157 duration of dual antiplatelet therapy after drug-eluting stent implantation, we avoid a common pitfa

158 MiStent is a drug-eluting stent with a fully absorbable polymer coati

159 onse to dosing with TCA cycle metabolite pro-drug esters, suggesting that the high levels of cellular

160 to categorize participants into high and low drug exposure groups.

161 vivo response, specifically whether systemic drug exposure is crucial for in vivo efficacy.

162 Maraviroc (MVC) is a candidate drug for HIV preexposure prophylaxis (PrEP).

163 izumab is important in choosing an anti-VEGF drug for the hundreds of thousands of patients with nAMD

164 ntify new disease biomarkers, and reposition drugs for diseases with unmet needs.

165 f selected ferrociphenols as new therapeutic drugs for such cancers.

166 uced toxicity as compared to the nontargeted drug formulations.

167 The activity of the "drug-free macromolecular therapeutics" is based on the b

168 In fact, none of the available drugs has shown clear evidence of disease-modifying acti

169 s is approximately 6-fold more enriched with drugs having published evidence of antiepileptic efficac

170 treated topically with available anti-cancer drugs (imiquimod and 5-fluorouracil).

171 mplicated in acquired resistance to platinum drugs in ovarian cancer.

172 Additionally, antifungal drugs, including amphotericin B, liposomal amphotericin

173 These drugs increased AhR recruitment onto the AhR-response el

174 o the central pattern generator (CPG) during drug-induced locomotor-like activity.

175 eutic strategy to protect against anticancer drug-induced peripheral neurotoxicity.

176 They were treated with 3-drug induction chemotherapy (vincristine, dactinomycin,

177 Of them, 14 drugs inhibited CYP27A1 by >/=75% and were evaluated for

178 the frontline colorectal cancer chemotherapy drug irinotecan.

179 Despite its efficacy, resistance to the drug is increasing.

180 we demonstrated that our set of repurposable drugs is approximately 6-fold more enriched with drugs h

181 Current quality control method for botanical drugs is mainly based on chemical testing.

182 n of SNCA following treatment with different drugs known to regulate alpha-SYN expression; while exog

183 nto the peritoneal cavity, enabling elevated drug levels versus intravenous (i.v.) injection.

184 In this study, we screened the FDA-approved drug library for agents that share significant similarit

185 oral bioavailability, ADMET risk filter for drug like features, and synthetic accessibility for chem

186 ganic molecules, drugs, drug metabolites and drug-like molecules, including salicylates and diclofena

187 elective human factor D (FD) inhibitors with drug-like properties.

188 ller, more rigid, more hydrophobic, and more drug-like than non-allosteric compounds.

189 Nevertheless, the lack of contamination by drugs may not be guaranteed.

190 -action compound related to the FDA-approved drug memantine, representing an uncompetitive/fast off-r

191 d a range of small organic molecules, drugs, drug metabolites and drug-like molecules, including sali

192 dosing software supplemented by therapeutic drug monitoring data should be embedded into daily pract

193 The results suggest that drug nanocrystals were taken up directly by the cells, a

194 ion (ARI) and nonsteroidal anti-inflammatory drugs (NSAIDs) use could trigger acute myocardial infarc

195 system (CNS)-targeted oligonucleotide-based drug (nusinersen/Spinraza) was approved by US Food and D

196 increase in the market share of nondetailed drugs of 0.84 percentage points (95% CI, 0.54 to 1.14 pe

197 h a decrease in the market share of detailed drugs of 1.67 percentage points (95% CI, -2.18 to -1.18

198 ABSTRACT: Ethanol, like other drugs of abuse, has both rewarding and aversive properti

199 RP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib.

200 g effects of cocaine and the effects of some drugs on cocaine self-administration.

201 We examined the impact of IS drugs on gut microbiota and on the expression of ileal a

202 w a patient will respond to a given proposed drug or treatment.

203 tors, such as nonsteroidal anti-inflammatory drugs or small interfering RNAs (siRNAs) against COX-1 a

204 However, as single-molecule drugs or synergistic mixtures, these remedies have faced

205 s about rare side-effects of anti-resorptive drugs, particularly bisphosphonates, and the absence of

206 er, there is a lack of knowledge as to which drug pharmacokinetic (PK) characteristics are key to gen

207 ve drug treatments, including with regard to drug pharmacology.

208 els were associated with a change in generic drug prices.

209 In vitro study showed more sustained drug release of CM-AL-containing scaffolds than these of

210 In this study, we performed a novel drug-repurposing screening to identify Food and Drug Adm

211 These well-known drug reservoirs can be used as smart carriers for multip

212 Most information about drug residues in eggs concern their concentrations in ra

213 ion is concerned about the presence of these drugs residues in honey as they often lead to health con

214 the multistage nature of the acquisition of drug resistance and provides a framework for understandi

215 e rate, the cases of recurrence and acquired drug resistance are concerning and highlight the need fo

216 with targeted drugs, which by selecting for drug resistance can drive metastatic progression, this s

217 Human immunodeficiency virus type 1 (HIV-1) drug resistance genotyping is recommended to help in the

218 oes not provide satisfactory efficacy due to drug resistance or reduced EGFR level.

219 molecular genotyping to assess antimalarial drug resistance selection and spread in the Greater Meko

220 yearly increases in the odds of pretreatment drug resistance were 23% (95% CI 16-29) in southern Afri

221 stance is increasingly compounded by partner drug resistance, causing high failure rates of artemisin

222 orrelate with stem cell pluripotency, cancer drug resistance, GSL storage disorders and other disease

223 cer evolution, intratumor heterogeneity, and drug resistance.

224 cer evolution, progression, and emergence of drug resistance.

225 are associated with high economic costs and drug resistance.

226 ed synthetic technologies and tested against drug-resistant bacterial strains.

227 atient care by providing faster detection of drug-resistant infecting strains and to help inform ther

228 tiative supported programmatic management of drug-resistant tuberculosis in 90 countries.

229 reveals complex gene networks which control drug response and illustrates how such data can add subs

230 of gene-environment interactions relevant to drug response and immunity, and we highlight how such im

231 The connection between genetic variation and drug response has long been explored to facilitate the o

232 terrogating mechanisms of mutation-dependent drug response, which will have a significant impact on c

233 ition of targetable proteins associated with drug responses further identified corresponding synergis

234 ellence [NICE] and the pan-Canadian Oncology Drug Review [pCODR]).

235 eceptors (MORs) are central to pain control, drug reward, and addictive behaviors, but underlying cir

236 he target of the first-line antituberculosis drug rifampin (Rif).

237 blicly available, high-quality DNA, RNA, and drug screening data.

238 omimetic assays for interaction analysis and drug screening involving membrane components.

239 signaling dynamics correlated strongly with drug sensitivity for 14 of the drugs, 9 of which had no

240 ature of cancer, but its global influence on drug sensitivity has not been examined.

241 models and models generated from Genomics of Drug Sensitivity in Cancer database shows the ability of

242 Ornithine uptake and the modulation of drug sensitivity in Trypanosoma brucei.

243 ize a functional assay to assess the ex vivo drug sensitivity of single multiple myeloma cells based

244 cell-specific dynamic signaling pathways and drug sensitivity.

245 ce of antibiotic stewardship when mitigating drug shortages.

246 Trazodone in particular, a licensed drug, should now be tested in clinical trials in patient

247 We found that the efficacy of 9 out of 24 drugs showed significant association with genetic load i

248 A survey of azole antifungal drugs showed that CYP126A1 is inhibited strongly by azol

249 s compared to controls administered with the drug solution only.

250 Such approaches promise to improve drug specificity by reducing off-target effects.

251 gma and low community participation, and STI drug stock-outs.

252 and antitumor activities of immunomodulatory drugs such as thalidomide, lenalidomide, and pomalidomid

253 1 actin regulators and three actin-targeting drugs suggest that PMS contains short actin filaments th

254 on, we found region-specific effects of each drug, suggesting both common and unique effects of imipr

255 stinct AML subclones, including differential drug susceptibilities of KRAS mutant and wild-type cells

256 nnels in the NAc may promote abstinence from drug-taking behaviors.

257 Our study identifies Vps34 as a new drug target for insulin resistance in Type-2 diabetes, i

258 gene expression programs and is an emerging drug target, but its oncogenic role is unclear.

259 functional families can be used to identify drug-target interactions, opening a new research directi

260 membrane protein functions, or involved with drug targeting and delivery.

261 Drugs targeting metabotropic glutamate receptor 5 (mGluR

262 nteracting molecules that could serve as new drug targets to treat APOL1-associated renal diseases.

263 bout molecular pathophysiology and potential drug targets.

264 n and reveals novel potential protein kinase drug targets.

265 odelling, therapeutic target identification, drug testing and regeneration.

266 Here we show that drugs that inhibit important kinases in the BCR signalin

267 For both drugs, the effect of myeloperoxidase activity was greate

268 We demonstrate the loading of two model drugs: the chemotherapeutic doxorubicin and the antibiot

269 The addition of drug then induces epigenetic reprogramming in these cell

270 leading many patients who could benefit from drug therapy to not take these drugs.

271 Compared to drug therapy, a resurgence of interest in using diet to

272 is engaged by the anti-diabetic sulfonylurea drugs to exert their full glucose-lowering effects.

273 uch and may represent peripherally available drugs to treat tactile-driven pain following neuropathy.

274 tion and expression of both major classes of drug transporters, SLC and ABC, in resting human blood n

275 ovide new insights into the heterogeneity of drug treatment effects.

276 ine health care settings, where adherence to drug treatment is unsupervised and therefore may be subo

277 ts; neither were considered related to study drug treatment.

278 Effective drug treatments for many psychiatric diseases are lackin

279 Here, we found that drug treatments or a genetic deficiency in the thioredox

280 hnology offers many possibilities to improve drug treatments, including with regard to drug pharmacol

281 ification of natural products and a marketed drug under mild conditions.

282 ing people with experiences of homelessness, drug use, imprisonment, and sex work.

283 f multiple neuropeptides in reinstatement of drug use, we formulated intranasal insulin to evaluate i

284 Nonsteroidal anti-inflammatory drugs use during ARI episodes, especially parenteral NSA

285 an accelerated approval of a particular new drug using an intermediate end point, such as MRD, would

286 sment of structure-function relationships of drugs using IM-MS.

287 Computational modeling evaluates drug vascular extravasation and diffusive transport as k

288 litating synthesis of the alkyl boronic acid drugs Velcade and Ninlaro as well as a boronic acid vers

289 The systemic exposure of the free drug was much lower than that achieved with the liposome

290 Study drugs were administered for up to 12 months.

291 challenge in treating cancers with targeted drugs, which by selecting for drug resistance can drive

292 small number of CCS values are available for drugs, which limits the use of CCS as an identification

293 ture-function relationship for each class of drugs with a specific target.

294 the association between preadmission use of drugs with anti-inflammatory effects and risk of new-ons

295 e are NMDA receptor (NMDAR) channel-blocking drugs with divergent clinical effects.

296 tolerance coexist and may be attenuated when drugs with NHE inhibitory actions are given concomitantl

297 New drugs with novel mechanisms of action, such as cardiac m

298 y replication, indicates that antiretroviral drugs with optimal penetration through the blood-brain b

299 ents who were exposed to any amount of study drug, with treatment assignment as treated, were include

300 antidepressant-like efficacy of three unique drugs, with reported rapid onset antidepressant properti